$44.32

-0.12 (-0.27%)

After Hours: $44.88 (+0.55, +1.25%)

Weekly Expected Move ±4.8%

$39 $42 $44 $46 $48

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Strong Buy · Power 73 · $7.5B mcap · 155M float · 1.33% daily turnover · Short 61% of daily vol

Credit Risk of going bust: lower than 62% of companies Debt: 17.4% of company value Bonds: none of note held by US funds details ▾

If the stock fell to about $0.75 (down 98%), Alkermes plc would be worth roughly what it owes.
Total debt $1.57B against a stock market value of $7.46B.
Distance to default 6.43 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $764.8M (short-term plus half of long-term), stock volatility 40.1%; Altman Z'' 1.67. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Overview Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Analysis Technicals Weather Peers ESG Institutions ETF Exposure Dark Pool Short Interest Supply Chain

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue

$1.5B -5.2% ▼

5Y CAGR: +7.3%

Gross Profit

$1.3B -2.9% ▼

5Y CAGR: +8.2%

Operating Income

$254M -39.6% ▼

Net Income

$242M -34.2% ▼

EPS (Diluted)

$1.43 -34.1% ▼

EBITDA

$331M -33.1% ▼

Profit Margins

Year-over-Year Growth

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$1.2B	$1.1B	$1.7B	$1.6B	$1.5B
YoY Growth	+13.0%	-5.3%	+49.6%	-6.4%	-5.2%
Cost of Revenue	$197M	$218M	$253M	$245M	$202M
Gross Profit	$976M	$894M	$1.4B	$1.3B	$1.3B
Gross Margin	83.2%	80.4%	84.8%	84.2%	86.3%
R&D Expenses	$291M	$273M	$271M	$245M	$324M
SG&A Expenses	$550M	$591M	$690M	$645M	$702M
Operating Expenses	$879M	$900M	$996M	$892M	$1.0B
Operating Income	$98M	-$6M	$414M	$421M	$254M
Operating Margin	8.3%	-0.5%	24.9%	27.0%	17.2%
Interest Expense	$11M	$13M	$23M	$23M	$12M
Income Before Tax	$88M	-$31M	$422M	$444M	$291M
Tax Expense	$11M	$2M	-$98M	$72M	$50M
Net Income	-$48M	-$158M	$356M	$367M	$242M
Net Margin	-4.1%	-14.2%	21.4%	23.6%	16.4%
EPS (Diluted)	$-0.30	$-0.97	$2.10	$2.17	$1.43
EBITDA	$178M	$60M	$519M	$495M	$331M
Shares Outstanding	161M	164M	170M	169M	169M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$378M	$430M	$307M	$391M	$394M	$385M	$393M	$496M
Cost of Revenue	$63M	$62M	$49M	$49M	$52M	$46M	$62M	$98M
Gross Profit	$315M	$368M	$257M	$341M	$343M	$338M	$331M	$398M
Gross Margin	83.3%	85.6%	83.9%	87.3%	86.9%	88.0%	84.3%	80.2%
R&D Expenses	$60M	$57M	$72M	$77M	$82M	$93M	$103M	$113M
SG&A Expenses	$150M	$147M	$172M	$171M	$172M	$187M	$265M	$218M
Operating Expenses	$210M	$205M	$244M	$248M	$254M	$280M	$380M	$380M
Operating Income	$105M	$163M	$14M	$93M	$89M	$58M	-$48M	$18M
Operating Margin	27.7%	37.8%	4.5%	23.8%	22.6%	15.1%	-12.3%	3.7%
Interest Expense	$6M	$5M	$0	$0	$0	$12M	$21M	$26M
Income Before Tax	$110M	$170M	$25M	$105M	$101M	$60M	-$62M	-$2M
Tax Expense	$17M	$24M	$3M	$18M	$18M	$11M	$5M	-$2M
Net Income	$92M	$147M	$22M	$87M	$83M	$49M	-$66M	$501K
Net Margin	24.4%	34.1%	7.3%	22.3%	21.0%	12.8%	-16.9%	0.1%
EPS (Diluted)	$0.55	$0.88	$0.13	$0.52	$0.49	$0.29	$-0.40	$0.00
EBITDA	$123M	$181M	$33M	$113M	$109M	$76M	-$22M	$54M
Shares Outstanding	167M	167M	169M	168M	169M	169M	166M	167M

ALKS NASDAQ